Matching articles for "constipation"
Issue 1721 · February 3, 2025
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom:…

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):17-24 doi:10.58347/tml.2025.1721a
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Issue 1721 · February 3, 2025
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)

View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):e1 doi:10.58347/tml.2025.1721c
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Issue 1721 · February 3, 2025
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)

View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):e1-3 doi:10.58347/tml.2025.1721e
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Issue 1683 · August 21, 2023
Linaclotide (Linzess) for Functional Constipation

The guanylate cyclase-C receptor agonist linaclotide ( Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):135-6 doi:10.58347/tml.2023.1683d
The guanylate cyclase-C receptor agonist linaclotide ( Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults. The drug has now been approved for treatment of functional constipation in patients 6-17 years old. Linaclotide is the only drug to be approved in the US for treatment of functional constipation.
Issue 1675 · May 1, 2023
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation

The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have…

Med Lett Drugs Ther. 2023 May 1; 65(1675):65-7 doi:10.58347/tml.2023.1675a
The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. It is the first drug-free treatment to be authorized by the FDA for this indication.
Issue 1594 · March 23, 2020
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel…

Med Lett Drugs Ther. 2020 Mar 23; 62(1594):41-8
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Issue 1573 · June 3, 2019
Prucalopride (Motegrity) for Chronic Idiopathic Constipation

The FDA has approved the 5-HT4 receptor agonist prucalopride ( Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US…

Med Lett Drugs Ther. 2019 Jun 3; 61(1573):86-8
The FDA has approved the 5-HT4 receptor agonist prucalopride ( Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Issue 1573 · June 3, 2019
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)

View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation

Med Lett Drugs Ther. 2019 Jun 3; 61(1573):e88-90
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
Issue 1571 · May 6, 2019 Free
In Brief: Tegaserod (Zelnorm) Returns

Tegaserod maleate (Zelnorm) , a 5-HT 4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with…

Med Lett Drugs Ther. 2019 May 6; 61(1571):72
Tegaserod maleate (Zelnorm) , a 5-HT 4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults <65 years old. In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic cardiovascular events (including cardiovascular death, nonfatal myocardial infarction [MI], and nonfatal stroke) in patients who took tegaserod than in those who took placebo. Among more than 11,600 patients treated with tegaserod for 1-3 months, 13 (0.11%) had a confirmed ischemic event compared to only 1 (0.01%) of more than 7000 patients who received placebo. 1 The mechanism by which tegaserod could cause cardiovascular ischemia is unknown; 5-HT 1 receptor agonists used to treat migraine, such as sumatriptan ( Imitrex , and others), can constrict coronary arteries, and tegaserod has some affinity for 5-HT 1 receptors. 1 Based on a re-examination of the data that led to withdrawal of tegaserod and the continued need for a drug with this mechanism of action to treat IBS-C, an FDA advisory committee recommended approval of a supplemental new drug application from a new sponsor (Sloan). The drug is now approved only for treatment of IBS-C in women <65 years old and is contraindicated in patients with a history of MI, stroke, transient ischemic attack, or angina. Prucalopride (Motegrity) , a selective 5-HT 4 receptor agonist recently approved by the FDA for treatment of CIC, will be reviewed in a future issue. It has less affinity for 5-HT 1 receptors than tegaserod. 2 In brief: tegaserod withdrawn. Med Lett Drugs Ther 2007; 49:40. J Tack et al. Systematic review: cardiovascular safety profile of 5-HT 4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35:745. Download complete U.S. English article
Issue 1535 · December 4, 2017
Naldemedine (Symproic) for Opioid-Induced Constipation

The FDA has approved the opioid receptor antagonist naldemedine ( Symproic – Shionogi) for treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain. Naldemedine is the third oral…

Med Lett Drugs Ther. 2017 Dec 4; 59(1535):196-8
The FDA has approved the opioid receptor antagonist naldemedine ( Symproic – Shionogi) for treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain. Naldemedine is the third oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved for this indication; naloxegol (Movantik) and methylnaltrexone (Relistor) were approved earlier.
Issue 1519 · April 24, 2017
Plecanatide (Trulance) for Chronic Idiopathic Constipation

The FDA has approved plecanatide ( Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess) , another guanylate…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):66-8
The FDA has approved plecanatide ( Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess) , another guanylate cyclase-C receptor agonist, and lubiprostone (Amitiza) , a chloride channel activator, were approved earlier for treatment of CIC in adults.
Issue 1504 · September 26, 2016
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as…

Med Lett Drugs Ther. 2016 Sep 26; 58(1504):121-6
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Issue 1478 · September 28, 2015
Naloxegol (Movantik) for Opioid-Induced Constipation

The FDA has approved naloxegol ( Movantik – AstraZeneca), a pegylated derivative of the opioid antagonist naloxone, for oral treatment of opioid-induced constipation in adults with chronic noncancer pain. It…

Med Lett Drugs Ther. 2015 Sep 28; 57(1478):135-7
The FDA has approved naloxegol ( Movantik – AstraZeneca), a pegylated derivative of the opioid antagonist naloxone, for oral treatment of opioid-induced constipation in adults with chronic noncancer pain. It is the only oral opioid antagonist approved for this indication in the US.
Issue 1418 · June 10, 2013
Lubiprostone (Amitiza) for Opioid-Induced Constipation

The FDA has approved use of lubiprostone (Amitiza) for treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug was previously approved for chronic idiopathic constipation and…

Med Lett Drugs Ther. 2013 Jun 10; 55(1418):47-8
The FDA has approved use of lubiprostone (Amitiza) for treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug was previously approved for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Issue 1403 · November 12, 2012
Linaclotide (Linzess) for Constipation

Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest), a guanylate cyclase-C receptor agonist, was recently approved by the FDA for oral treatment of chronic idiopathic constipation (CIC) and…

Med Lett Drugs Ther. 2012 Nov 12; 54(1403):91-2
Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest), a guanylate cyclase-C receptor agonist, was recently approved by the FDA for oral treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. It is the second drug approved for this indication; lubiprostone (Amitiza) , a metabolite of prostaglandin E1, was the first.
Issue 1312 · May 18, 2009
Colon Cleansing

Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.

Med Lett Drugs Ther. 2009 May 18; 51(1312):39-40
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
Issue 1292 · August 11, 2008
Methylnaltrexone (Relistor) for Opioid-Induced Constipation

The FDA has approved subcutaneous injection of methylnaltrexone ( Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced…

Med Lett Drugs Ther. 2008 Aug 11; 50(1292):63-4
The FDA has approved subcutaneous injection of methylnaltrexone ( Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.
Issue 1290 · July 14, 2008
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation

Lubiprostone (Amitiza) , which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with…

Med Lett Drugs Ther. 2008 Jul 14; 50(1290):53-4
Lubiprostone (Amitiza) , which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Issue 1260 · May 7, 2007 Free
In Brief: Tegaserod (Zelnorm) Withdrawn

Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of…

Med Lett Drugs Ther. 2007 May 7; 49(1260):40
Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women, 1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect. 2 The FDA now has requested that the manufacturer stop marketing the drug based on an unpublished postmarketing analysis of earlier clinical trials that showed a higher rate of serious cardiovascular events (including angina, myocardial infarction and stroke) in patients who took tegaserod compared to placebo. Among more than 11,600 patients treated with tegaserod for 1-3 months, 13 (0.11%) had a confirmed ischemic event compared to only 1 patient (0.01%) among more than 7000 treated with placebo. The mechanism by which tegaserod would cause cardiovascular ischemia is unknown; serotonin 5-HT 1 receptor agonists used to treat migraine, such as sumatriptan (Imitrex) , can constrict coronary arteries, and tegaserod has some affinity for 5-HT 1 receptors. 3 Tegaserod may still be available, possibly through a special access program, for patients who do not have other treatment options. 1. Tegaserod maleate (Zelnorm) for IBS with constipation. Med Lett Drugs Ther 2002; 44:79. 2. Drugs for irritable bowel syndrome. Treat Guidel Med Lett 2006; 4:11. 3. AJ Busti et al. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24:526. Download U.S. English
Issue 1236 · June 5, 2006
Lubiprostone (Amitiza) for Chronic Constipation

The FDA has approved lubiprostone ( Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for…

Med Lett Drugs Ther. 2006 Jun 5; 48(1236):47-8
The FDA has approved lubiprostone ( Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for this indication (in 2004 for adults <= 65 years old) is tegaserod (Zelnorm) , a partial agonist of serotonin that is also approved for constipation-predominant irritable bowel syndrome in women. Of course, numerous over-the-counter products are available for treatment of constipation.
Issue 43 · March 1, 2006
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort…

Treat Guidel Med Lett. 2006 Mar; 4(43):11-6
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort and altered bowel habits.
Issue 1139 · September 16, 2002
Tegaserod Maleate (Zelnorm) for IBS with Constipation

Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is…

Med Lett Drugs Ther. 2002 Sep 16; 44(1139):79-80
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex) , which was withdrawn previously because of toxicity, will soon be available again for women with severe diarrhea-predominant IBS ( Medical Letter 2002; 44:67 ).